AI Image
Novo says CagriSema shows greater weight loss than Lilly rival in diabetes patients
Reuters • • business
Key Points:
- Novo Nordisk's new obesity drug, CagriSema, is positioned as a successor to its weight-loss drug Wegovy, aiming to regain market share lost to Lilly following Wegovy's patent expiry after 2030.
- In a recent head-to-head trial, CagriSema's 1 mg dose outperformed Lilly's tirzepatide 5 mg in weight loss, though analysts noted tirzepatide's superiority at higher doses limits the impact of these results.
- CagriSema combines cagrilintide and semaglutide and is planned for launch early next year, with a U.S. FDA decision expected in the fourth quarter.
- Novo's shares fell over 4% amid concerns about pricing power and strategy ahead of upcoming patent expiries, despite positive trial results showing significant weight loss and comparable blood sugar reductions in diabetic patients.
